Method of treating amykloidosis comprising administering an anti-HMGB-1 antibody
US8470325B2 · kind B2 · utility
0Cited by
7References
4Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Feb 15, 2008 |
| Grant date | Jun 25, 2013 |
| Priority date | — |
| Expiry date | Apr 9, 2028 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Previously, it was difficult to obtain high-affinity antibodies that specifically bind to HMGB-1 but not to HMGB-2. Under this circumstance, the present inventors successfully obtained antibodies that are more reactive to HMGB-1 than to HMGB-2 by using specific peptides as an antigen. The present inventors also demonstrated that the antibodies had a HMGB-1-neutralizing activity. The present inventors administered the antibodies to amyloidosis model animals, and as a result, successfully demonstrated that the antibodies produced a significant therapeutic effect.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.